Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

7.8%

16 terminated/withdrawn out of 206 trials

Success Rate

87.0%

+0.5% vs industry average

Late-Stage Pipeline

15%

31 trials in Phase 3/4

Results Transparency

3%

3 of 107 completed trials have results

Key Signals

32 recruiting3 with results13 terminated

Enrollment Performance

Analytics

N/A
77(50.3%)
Phase 2
37(24.2%)
Phase 3
19(12.4%)
Phase 4
12(7.8%)
Phase 1
8(5.2%)
153Total
N/A(77)
Phase 2(37)
Phase 3(19)
Phase 4(12)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (206)

Showing 20 of 206 trials
NCT03322865Phase 2Active Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

Role: collaborator

NCT06877143Not ApplicableRecruiting

Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis

Role: lead

NCT03474744Phase 2Active Not Recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Role: collaborator

NCT05099471Phase 2Recruiting

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

Role: collaborator

NCT04820478Not ApplicableCompleted

Efficacy and Tolerability of Beta Hydroxybutyrate Ester in Patients With Amyotrophic Lateral Sclerosis (ALS)

Role: lead

NCT04871035Recruiting

Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)

Role: lead

NCT04881682Phase 2Recruiting

Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Role: lead

NCT06280079Not ApplicableRecruiting

Ultra-high-caloric, Fatty Diet in ALS

Role: lead

NCT07239843Enrolling By Invitation

Prospective Observational Study of the Relationship Between Sociodemographic Factors, Blood-based Biomarkers and Psychiatric Symptoms in Neurodegenerative Diseases and Mental Disorders

Role: collaborator

NCT07543705Not Yet Recruiting

Glucose-Level During Endurance Exercise

Role: lead

NCT04628026Phase 3Recruiting

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Role: lead

NCT07436195Recruiting

Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA

Role: lead

NCT07466173Not ApplicableNot Yet Recruiting

The Importance of Insulin Action in the Brain for the Immune System During Physical Activity-Overweight

Role: lead

NCT04268277Phase 2Terminated

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Role: lead

NCT07374705Recruiting

Disentangling the Effect of Brain Insulin Resistance on Brain Health

Role: collaborator

NCT07314190Enrolling By Invitation

Retrospective Observational Study of Blood-based Biomarkers in the Diagnosis and Monitoring of Patients With a Neurodegenerative Disease or Mental Disorder

Role: collaborator

NCT06295640Not ApplicableActive Not Recruiting

Relative Contribution of Brain Insulin Action for Postprandial Metabolism

Role: lead

NCT06709846Recruiting

Magnetic Resonance Imaging in Metabolic Diseases

Role: lead

NCT07410637Not ApplicableRecruiting

Impact of Thyroid Hormones on Human Glucose and Energy Metabolism

Role: lead

NCT01252485Recruiting

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project

Role: lead